ANI Pharmaceuticals | ANIP - Selling And Administration Expenses


ANI Pharmaceuticals reported $82.79M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Heron Therapeutics USD 23.74M 605K Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Perrigo USD 255.9M 10.2M Dec/2025
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025